百时美施贵宝(Bristol Myers Squibb)日前在欧洲血液学协会(EHA)年会上,展示了其靶向蛋白降解平台的最新研究数据,包含该公司在研的口服E3泛素连接酶cereblon调节剂(CELMoD)药物mezigdomide(MEZI)和iberdomide(IBER)在多发性骨髓瘤(MM)患者中的更新临床研究结果,以及golcadomide(GOLCA)在非霍奇金淋巴瘤(NHL)中的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.